# Asher Biotherapeutics

Source: https://onco.cc/companies/asher-bio/  
OnCo record `asher-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Asher Bio engineers immune-stimulating molecules that switch on only one type of immune cell, such as killer T cells, so the drug is more potent against tumours and causes fewer side effects.

## Summary

Asher Biotherapeutics builds cis-targeted immunotherapies: a cytokine fused to an antibody arm that binds a marker on the intended cell type, so the cytokine acts selectively rather than on every cell bearing its receptor. The lead programme AB248 is a CD8-targeted interleukin-2 in phase 1 for advanced solid tumours, alone and with pembrolizumab; a second programme targets regulatory T cells for autoimmune disease. The company was founded with Third Rock Ventures, went through YC, and has raised Series A and B rounds; amounts are not recorded here because no primary source was fetched.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.asherbio.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/asher-bio
- Official website: https://www.asherbio.com

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [Third Rock Ventures](https://onco.cc/companies/third-rock-ventures/), [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/asher-bio.json